The Endocrinology Network® Cardiology clinical resource center is a hub of news related to cardiovascular health that is relevant to clinicians interested in endocrinology. This page will host relevant content about cardiology and cardiovascular disease including guideline updates, new studies and breakthroughs, and clinical perspectives for practicing clinicians.
May 17, 2022
Diabetic ketoacidosis increased the likelihood of in-hospital mortality by 61%, the likelihood of major adverse cardiovascular events by 56%, and a likelihood of 30-day readmission by 12% among patients hospitalized with heart failure in the US.
May 05, 2022
A 3-month trial found reducing sedentary time by just an hour per day was enough to produce statistically significant changes in biomarkers for cardiovascular risk among patients with metabolic syndrome.
May 02, 2022
New data suggests the number of prescriptions for SGLT2 inhibitors in the US has doubled since 2015 with prescriptions for GLP-1 receptor agonists tripling during the same time period.
April 28, 2022
An analysis of data from a Cleveland Clinic database indicates calcium supplementation in older adults with aortic stenosis was linked to an increased risk of mortality and worsening aortic stenosis.
April 25, 2022
An analysis of the DAPA-HF trial provides insight into the occurrence of eGFR dips in the first 14 days following initiation of therapy with an SGLT2 inhibitor and their association with long-term outcomes.
April 21, 2022
Analysis of the REWIND trial indicates cognitive impairment among patients with diabetes was associated with a 1.6 times greater risk of major adverse cardiovascular events and a 1.8 times greater risk of stroke or mortality.
April 18, 2022
A microsimulation model provides insight into potential years of life expectancy gained by meeting recommended treatment goals for HbA1c, LDL-C, BMI, and blood pressure among adult patients with type 2 diabetes.
April 07, 2022
A prespecified analysis of FIDELITY details the effects of finerenone against placebo therapy for reducing the risk of cardiovascular events based on history of ASCVD among patients with type 2 diabetes and chronic kidney disease.
April 06, 2022
A study from Intermountain Healthcare provides insight into the tolerability and clinical impact and tolerability of initiating combination therapy with both SGLT2 inhibitors and GLP-1 RAs compared against monotherapy with either agent.
February 25, 2022
New research suggests pregnancies conceived with assisted reproductive technology were associated with a more than doubling in risk for acute kidney injury.